ãããšååŽçãšå€§è£
è©å€ãããã³ã¹ã¡ã§ãã䜿ã£ãŠã¿ããçã¿ãèèããèµ·ããããšããããŸããèªåã«åããªãæåïŒæ·»å ç©ïŒãå
¥ã£ãŠããã®ã ãšèããŠã次åããã¯ãã®æåãå
¥ã£ãŠããªããã®ãéžã¶ã§ããããã§ã¯ã䜿çšåäŸããªãæ·»å ç©ãå«ãŸããŠããããã©ãã§ããããã䜿ã£ãŠã倧äžå€«ããäžå®ã«æãã®ã¯åœç¶ã§ããã³ã¹ã¡ã§ãããæ
éã«èãã人ã¯ããŸããäœã®äžã«æ³šå
¥ããããã®ã«å¯ŸããŠãªãããªãããæ
éã«ãªãã§ãããããã®äžå®ã¯ããããããšããŠåŠå®ããããããªãã®ãªã®ã§ããããã
ãçç¥ãããããšãªã宿œã
ãã¬ãã®ãã¥ãŒã¹çªçµã§åŠå®ããã ãã§ãªããæ²³é倧è£ã¯èªèº«ã®ããã°ã§ããã¯ã¯ãã³ããã«ã€ããŠããšããèšäºãå ¬éããŸããã
ãããšããŠåŠå®ããŠãããã®ã®äžã«ã¯ãååŽçããã¡ã€ã¶ãŒç€Ÿãã¢ãã«ã瀟ãFDAãªã©ã®è³æãšç°ãªãèŠè§£ããããŸãã
ãæ²»éšãçµãã£ãŠããªãã®ã§å®å šæ§ã確èªãããŠããªãã
ïœïŒ²ïŒ®ïŒ¡ã¯ã¯ãã³ã¯ãåºç€ç ç©¶ãåç©å®éšãæ²»éšãçç¥ãããããšãªã宿œããããªã¹ã¯ãäžåãèšåºçã«æå³ã®ããæå¹æ§ã確èªãããŠããŸãã
ãã®äžã§ããã€ãŸã§å¹æãæç¶ããããšããé·æã®æå¹æ§ã確èªããããã®æ²»éšãç¶ç¶ããŠè¡ãããŠããŸãã
ãšã倧è£ã®ããã°ã«æžãããŠããŸãã
äžæ¹ãFDAã®ãã¡ã¯ãã·ãŒãã«ã¯ãäžèšã®ããã«æžãããŠããŸãã
The Pfizer-BioNTech COVID-19 Vaccine has not undergone the same type of review as an FDA-approved or cleared product.
Pfizer-BioNTech COVID-19ã¯ã¯ãã³ã¯ãFDAãæ£åŒã«æ¿èªãŸãã¯èªå¯ãã補è¬ãšåæ§ãªå¯©æ»ãåããŠããŸããã
These may not be all the possible side effects ofthe Pfizer-BioNTech COVID-19 Vaccine. Serious and unexpected side effects may occur. Pfizer-BioNTech COVID-19 Vaccineis still being studiedin clinical trials.
Pfizer-BioNTech COVID-19ã¯ã¯ãã³ã®èããããå¯äœçšã¯ããã以å€ã«ãããå¯èœæ§ããããŸããäºæããªãæ·±å»ãªå¯äœçšãçºçããå¯èœæ§ããããŸããPfizer-BioNTech COVID-19ã¯ã¯ãã³ã¯ããŸã èšåºè©Šéšã§èª¿æ»äžã§ãã
ãã¡ã¯ãã·ãŒãã«ã€ããŠã¯ãVol.14ã§åãäžããŠããŸãã
ç¶ããŠãååŽçã®ãµã€ãã§å ¬éãããŠãããã³ãããã£ç泚ãç¹äŸæ¿èªã«ä¿ãå ±åæžããèŠãŠã¿ãŸãããã
åçåŽåçãµã€ããããŒã > æ¿çã«ã€ã㊠> 審è°äŒã»ç ç©¶äŒç > åçç§åŠå¯©è°äŒ (äºé²æ¥çš®ã»ã¯ã¯ãã³åç§äŒ)> 第19å 2021幎2æ15æ¥ãè³æ> 11ãåèè³æïŒãæ°åã³ããã¯ã¯ãã³ãã³ãããŠã€ã«ã¹ä¿®é£ŸãŠãªãžã³RNA ã¯ã¯ãã³ïŒSARS-CoV-2ïŒïŒã³ãããã£ç泚ïŒãïŒãã¡ã€ã¶ãŒç€ŸïŒå¯©æ»å ±åæžïŒç¹äŸæ¿èªã«ä¿ãå ±åæžïŒ.pdf
ãç¹äŸæ¿èªã«ä¿ãå ±åæžãã«ã€ããŠã¯ãVol.1ã§è©³ããåãäžããŠããŸãã

12ããŒãžã«ããå®å
šæ§è¬ç詊éšã宿œããŠããªãããšæžãããŠããŸãã
å®å
šæ§è¬ç詊éšã¯ãåç©ãçšããæ¯æ§è©Šéšãšã¯å¥ã«ãèšåºè©Šéšåã«å®æœããŠããã¹ãéèŠãªè©Šéšã§ãã
ãã³ãããã£ç泚ãç¹äŸæ¿èªã«ä¿ãå ±åæžãã®19ããŒãžã«ã¯ãã©ããã䜿ã£ãæ¯æ§è©Šéšã§ãèèã«åœ±é¿ããã£ããšæžãããŠããŸãã

ããã«ã€ããŠã¯Vol.2ã§åãäžããŸãããããæšå¯ãã§çã¥ããŠããŸãã
ããããèªããšãçç¥ããŠããªããšã¯æããŸããããããéçºéå§ããèšåºè©Šéšéå§ãŸã§ããããŸãã«ãçãã

éçºãéå§ããæãé»å¡ãã«ãªã£ãŠããŸãããWHOãæŠæŒ¢åžã§çºçããèºçãæ°åã³ãããŠã€ã«ã¹ã«ãããã®ã ãšçºè¡šããã®ãã1æ12æ¥ãªã®ã§åœç¶ãã以éã§ãããã1æã ãšããŠãã4æã«ããã«æ¥çš®ãå§ããã®ã¯æ©ãããŸãã
ãç¹æ®µã®äžå®ã¯ãªãã
ããã«ã倧è£ã¯ããã°ã§äžèšãåŠå®ããŠããŸãã
ãé·æçãªå®å šæ§ãããããªãã
ïœïŒ²ïŒ®ïŒ¡ã¯åæ¥ããæ°æ¥ã§åè§£ãããã¯ã¯ãã³ã«ããäœãããã¹ãã€ã¯èçœãçŽïŒé±é以å ã§ã»ãšãã©ããªããªããŸãã
ïœïŒ²ïŒ®ïŒ¡ã¯ã¯ãã³ãéºäŒåã«çµã¿èŸŒãŸããããšã¯ãããŸããã
ïœïŒ²ïŒ®ïŒ¡ã¯ã¯ãã³ã§ãã¢ããã£ã©ãã·ãŒãèµ·ããããšããããŸãããçç¶ãåºãã®ã¯æ¥çš®ããŠããïŒæ¥ä»¥å ã«éãããŸãã
ãããŸã§ã®ã¯ã¯ãã³ã§ããã»ãšãã©ã®å¯åå¿ãïŒïŒïŒé±é以å ã«èµ·ããããšãç¥ãããŠããŸãã
以äžã®ããšãããã³ããã¯ã¯ãã³ã®é·æçãªå®å šæ§ã«ã€ããŠç¹æ®µã®äžå®ããããšããããšã¯ãããŸããã
ãé·æçãªå®å
šæ§ãããããªãããšæãããšãããªããããªã®ã§ããããã
é·æçãªå®å šæ§ãšã¯ãã¢ããã£ã©ãã·ãŒãæ·»ä»ææžã«å¯åå¿ãšããŠæžãããŠãããã®ã«ã€ããŠã ãã§ã¯ãªãã¯ãã§ãããããŠãã®ã¯ã¯ãã³ã¯ãããããŸã§ã®ã¯ã¯ãã³ããšã¯éããŸãã
æ¥çš®åžãšäžç·ã«éãããŠãããæ°åã³ããã¯ã¯ãã³äºé²æ¥çš®ã«ã€ããŠã®èª¬ææžãã«ã¯ãäžèšã®ããã«æžãããŠããŸãã

ãæ¬ã¯ã¯ãã³ã¯ãæ°ããçš®é¡ã®ã¯ã¯ãã³ã®ããããããŸã§ã«æããã«ãªã£ãŠããªãçç¶ãåºãå¯èœæ§ããããŸãããšæžããŠãããŸãã
æããã«ãªã£ãŠããªãçç¶ãåºãå¯èœæ§ãããã®ã«ããªããç¹æ®µã®äžå®ããªãããšèšããã®ã§ããããã

ãã³ãããã£ç泚ãç¹äŸæ¿èªã«ä¿ãå ±åæžã9ããŒãžã«ã¯ã䜿çšåäŸããªãæ·»å å€ãå«ãŸããŠãããšæžãããŠããŸããé»å¡ãã«ãããŠãããã®ãŸã§å«ãŸããŠããã®ã«ãäžå®ã«æã£ãŠã¯ãããªãã®ã§ããããïŒ
åãããã³ãããã£ç泚ãç¹äŸæ¿èªã«ä¿ãå ±åæžãã®37ããŒãžã«ã¯ããçŸæç¹ã§æ¬å€ã®æ¥çš®åŸé·æã®ååãªå®å šæ§ããŒã¿ã¯åŸãããŠããªãããšæžãããŠããŸãã

45ããŒãžã53ããŒãžã«ãäžèšã®ããã«æžãããŠããŸãã




é·æçãªå®å
šæ§ã¯ããããªãããã調æ»ãç¶ãããšæžãããŠããŸããååŽçã®è³æãšå€§è£ã®èãã¯ãæããã«éã£ãŠãããšæããŸãã
ãå¯èœæ§ã¯èãã«ããã
ååŽçã®è³æã§ã¯ãçŸæ£å¢åŒ·ããšæžãããŠããããADEãã®å¯èœæ§ã«ã€ããŠãã倧è£ã¯ãããšããŠæ±ã£ãŠããŸãã
ãïŒ¡ïŒ€ïŒ¥ïŒæäœäŸåæ§å¢åŒ·çŸè±¡ïŒãèµ·ããã
ã¯ã¯ãã³ãéå»ã®ææã«ããäœãããæäœãããŠã€ã«ã¹ã®ææãå¢åŒ·ããŠããŸãããšããšãããŸãã
ãã³ã°ç±ã¯ã¯ãã³ãã¯ã¯ãã³ã§ãã®ãããªããšãèµ·ããããšããããŸãã
ãããããã¡ã€ã¶ãŒç€Ÿãšã¢ãã«ã瀟ã®ïœïŒ²ïŒ®ïŒ¡ã¯ã¯ãã³ã§ã¯ãé«ãäžåäœçšãããæäœãšãã©ã³ã¹ã®ãããªã³ãçã®åãã確èªãããåç©å®éšã§ãã¯èгå¯ããããå€§èŠæš¡ãªæ²»éšã«ãããŠãã®å ±åã¯ãªãããšãããæ°åã³ããã¯ã¯ãã³ã«é¢ããŠãã®å¯èœæ§ã¯èãã«ãããšãããŠããŸãã
ããã«ã€ããŠã¯ããã³ãããã£ç泚ãç¹äŸæ¿èªã«ä¿ãå ±åæžã15ããŒãžã53ããŒãžã«æžãããŠããŸãã

åç©å®éšãããã®ã¯ãé¡äŒŒããSARS-CoVã§ãããSARS-CoV2ã§ã¯å®æœããŠããªãã®ã§ã¯ãªãã§ããããã

ååŽçã®è³æã§ã¯ããå¯èœæ§ã¯ããããšããŠããŸããçŸæç¹ã§ã¯ããããªãããšãããªãããã ãšèšãåãã®ã§ããããããèªèº«ã®æç« ã§ãããã®å¯èœæ§ã¯èãã«ãããšãããŠããŸãããšèšã£ãŠããããå¯èœæ§ã¯ãããŸããããšã¯èšã£ãŠããŸãããå®å šã«åŠå®ã§ããªãããšãªã®ã«ããªãããããããããšããŠæ±ãã®ã§ããããã
远èšïŒ
ãã®åŸããã¡ã€ã¶ãŒç€Ÿã®ãªã¹ã¯ç®¡çèšç»æžã«ããADEã«ãã£ãŠéçåããå¯èœæ§ããããšèããããããšæžãããŸããã
ã¢ãã«ã瀟ã®ãªãªãŒã¹
ã¢ãã«ã瀟ãã12æ³ãã17æ³ãžã®æå¹æ§ã100%ã ã£ããšããæ²»éšçµæãçºè¡šãããªãªãŒã¹ã®æåŸã«ã¯ãäžèšã®ããã«æžãããŠããŸãã
The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Modernaâs control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements.
å°æ¥ã®èŠéãã«é¢ããŠãã®ãªãªãŒã¹ã«æžãããŠããããšã¯ãçŽæã§ãä¿èšŒã§ããããŸããããããã®å°æ¥ã®èŠéãã«é¢ããèšè¿°ã¯ãæ¢ç¥ããã³æªç¥ã®ãªã¹ã¯ãäžç¢ºå®æ§ãããã³ãã®ä»ã®èŠå ã䌎ããããé床ã«ä¿¡é Œããã¹ãã§ã¯ãããŸããããã®å€ãã¯Modernaã®å¶åŸ¡ã®åã°ãªããã®ã§ãããå®éã®çµæãããããã®å°æ¥ã®èŠéãã«é¢ããèšè¿°ã«ãã£ãŠè¡šæãŸãã¯æç€ºãããŠãããã®ãšå€§ããç°ãªãå¯èœæ§ããããŸãã
ãã¡ã€ã¶ãŒç€Ÿã®ãªãªãŒã¹ã«ããåããããªããšãæžãããŠããŸãããã¡ã€ã¶ãŒç€Ÿãã¢ãã«ã瀟ã§ãããé·æçãªå®å šæ§ã«ã€ããŠæèšããŠããªãã®ã«ããªã倧è£ãããã ãšèšãåãã®ã§ããããã
ãããŠãååŽçãå»åž«ã«å¯ŸããŠãç©æ¥µçã«å ±åããŠã»ããããšãã£ãŠããããããã®çç¶ã¯ãäœãæå³ããŠããã®ã§ããããã
ã¯ã¯ãã³æ¥çš®ãšã®å æé¢ä¿ã瀺ãããŠããªãçç¶ãå«ããå¹ åºãè©äŸ¡ãè¡ããããåœé¢ã®éã以äžã®çç¶ã«ã€ããŠãå ±åãç©æ¥µçã«ãæ€èšãã ãããã
ãããããã®ã©ã³ã»ãã¬çåçŸ€ãæ¥æ§æ£åšæ§è³èé«çïŒADEMïŒãè¡å°æ¿æžå°æ§çŽ«æç ãè¡ç®¡çãç¡èæ§é«èçãè³çã»è³çãé¢ç¯çãèé«çãå¿ççãé¡é¢ç¥çµéº»çºãè¡ç®¡è¿·èµ°ç¥çµåå°ïŒå€±ç¥ã䌎ããã®ïŒ
äžèšã«ã€ããŠã¯ãVol.23ã§åãäžããŠããŸãã
